COVID-19 associated viral myocarditis: does it exist?

Vaishali Verma¹, Sachin Sondhi², Rajesh Sharma¹, Kunal Mahajan¹

¹Department of Cardiology, Indira Gandhi Government Medical College, Shimla; ²ACE Heart and Vascular Institute, Chandigarh, India

Dear Editor

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is a lethal pandemic that has claimed millions of lives worldwide. While respiratory involvement is the most common and most virulent manifestation of COVID-19, there is enough data to suggest that myocardial injury reflected through elevated troponin levels is seen in around 7-28% of patients and is related with increased morbidity and mortality (Figure 1) [1,2,3].

Researchers have proposed various mechanisms through which infection with SARS-CoV-2 can lead to myocardial injury [4]. The most commonly proposed hypothesis is the myocardial injury as a result of the cytokine storm induced inflammatory cascade. This inflammatory hypothesis is evident by parallel rise of inflammatory biomarkers like interleukin-1, C-reactive protein, etc., along with the rise in cardiac troponins [4]. Other suggested mechanisms include acute inflammation-triggered plaque destabilization resulting in acute coronary syndrome, microvascular injury secondary to disseminated intravascular coagulation and thrombosis, and oxygen supply-demand mismatch induced myocardial injury (Type 2 myocardial infarction) [2-4].

Another important mechanism which has been hypothesised is the direct invasion of myocardium by the virus itself resulting in acute viral myocarditis. This hypothesis is based on the observations from previous coronavirus infections including SARS-CoV-1, where viral myocarditis was documented and viral genomes were isolated from the affected myocytes [4,5]. With the ever increasing recognition of occurrence of myocardial injury in COVID-19 and its ill effect on the prognosis, it has become a priority for the researchers to extensively study the pathogenetic mechanisms involved [2,3]. We reviewed the literature and collected all reports pertaining to COVID-19 associated viral myocarditis. Interestingly, we found that the diagnosis of viral myocarditis was made on clinical and imaging grounds in majority of the cases of COVID-19. Some of these reports documented myocardial interstitial inflammation and edema on cardiac magnetic resonance imaging [6-10], while a few studies demonstrated interstitial inflammatory infiltrates on endomyocardial biopsy [7,11]. Only in one of the reports, SARS CoV-2 genome could be isolated from endomyocardial biopsy but that too from the interstitial macrophages that had probably infiltrated into the myocardium from the lungs [11]. Similarly one of the autopsy series also didn’t reveal any cardiac myocyte necrosis [12]. Thus, all the available data regarding the occurrence of viral myocarditis in COVID-19 is anecdotal and we still do not have any endomyocardial biopsy documentation that SARS-CoV-2 does invade the myocytes. Despite the likely hypothesis that explains the myocardial involvement in COVID disease is an exaggerated inflammatory response caused by the virus, a directed myocardial invasion cannot be excluded because of the lack of data. Endomyocardial biopsy is the definitive diagnostic tool for myocarditis, however, the feasibility of performing endomyocardial biopsies in all suspected cases is questionable especially considering the contagious spread risk, expertise required, and the false negative rate [13]. Furthermore, during this kind of pandemic, performing an endomyocardial biopsy to confirm or exclude acute viral myocarditis in patients with signs and symptoms of acute heart failure, and with suggestive features at cardiac MRI and without other plausible causes is unthinkible. Nevertheless, there are currently no specific antiviral or anti-inflammatory treatment options available against COVID-19 associated myocarditis, therefore, from the therapeutic perspective also, knowing the exact mechanisms underlying the myocardial involvement remains debatable, and would not change the treatment options that include heart failure treatment and arrhythmias control.

On the contrary, endomyocardial biopsy serves as an opportunity for the accurate diagnosis and provides tissues which can be
explored for the development of specific cardiac biomarkers useful for diagnosing COVID-19 associated myocarditis and may also lead to discovery of new biological pathways for treatment against COVID-19. We suggest that whenever feasible, in case of death of a patient with COVID-19 associated myocarditis, autopsy can be performed to study the gross and microscopic pathology of the heart and to test the presence of viral genomes. Furthermore, if coronary angiography is deemed necessary in a patient with COVID-19 associated cardiac involvement, it is reasonable to simultaneously perform the right heart catheterization and endomyocardial biopsy if the facilities and expertise exist. This may provide new pathogenetic insights and knowledge that is critically needed in this trying time.

References